QGEN:NGS-Qiagen N.V. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 45.81

Change

-0.21 (-0.46)%

Market Cap

USD 6.46B

Volume

0.93M

Analyst Target

USD 52.64
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Qiagen NV provides sample and assay technologies. It also offers kits, assays, related automated systems and bioinformatics solutions, that cover the entire continuum from basic life sciences research to clinical diagnostics.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-28 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

+1.76 (+0.65%)

USD 192.25B
IQV IQVIA Holdings Inc

+0.30 (+0.13%)

USD 45.24B
A Agilent Technologies Inc

+0.92 (+0.67%)

USD 39.45B
LH Laboratory Corporation of Amer..

+1.07 (+0.49%)

USD 18.80B
DGX Quest Diagnostics Incorporated

-0.38 (-0.25%)

USD 17.18B
CRL Charles River Laboratories

+4.29 (+2.21%)

USD 9.70B
VNRX Volitionrx Ltd

-0.02 (-2.86%)

USD 0.06B
ENZ Enzo Biochem Inc

-0.02 (-1.77%)

USD 0.06B
MTD Mettler-Toledo International I..

+9.66 (+0.70%)

N/A
TMO Thermo Fisher Scientific Inc

-2.99 (-0.49%)

N/A

ETFs Containing QGEN

EXS2:XETRA iShares TecDAX® UCITS ET.. 7.68 % 0.00 %

+0.27 (+1.41%)

USD 0.77B
EXIB:XETRA iShares TecDAX® UCITS ET.. 7.68 % 0.00 %

+0.04 (+1.41%)

USD 0.77B
TDXPEX:SW iShares TecDAX® UCITS ET.. 7.68 % 0.00 %

N/A

USD 5,933.97B
E908:XETRA Lyxor 1 TecDAX (DR) UCITS.. 7.62 % 0.00 %

+0.22 (+1.41%)

USD 0.09B
CB1TX:SW Lyxor 1 TecDAX (DR) UCITS.. 7.24 % 0.00 %

+0.16 (+1.41%)

N/A
CF1:PA Amundi MSCI France UCITS 4.81 % 0.00 %

+1.85 (+1.41%)

USD 8.45M
DDOC:XETRA Global X Telemedicine & D.. 4.19 % 0.00 %

+0.13 (+1.41%)

USD 5.39M
DDOC:F Global X Telemedicine & D.. 4.19 % 0.00 %

+0.17 (+1.41%)

USD 4.62M
EDOC:LSE Global X Telemedicine & D.. 4.17 % 0.00 %

+0.18 (+1.41%)

USD 3.76M
EDOG:LSE Global X Telemedicine & D.. 4.17 % 0.00 %

+0.10 (+1.41%)

USD 0.23M
EDOC Global X Telemedicine & D.. 4.13 % 0.00 %

+0.14 (+1.41%)

USD 0.04B
EKG First Trust Nasdaq Lux Di.. 4.13 % 0.00 %

+0.15 (+1.41%)

USD 2.48M
EDOC:SW Global X Telemedicine & D.. 4.03 % 0.00 %

+0.11 (+1.41%)

N/A
GNOM Global X Genomics & Biote.. 3.90 % 0.00 %

+0.34 (+1.41%)

USD 0.08B
GNOG:LSE Global X Genomics & Biote.. 3.83 % 0.00 %

+0.14 (+1.41%)

USD 6.11M
CURG:LSE VanEck Genomics and Healt.. 3.73 % 0.00 %

+0.21 (+1.41%)

USD 6.97M
MVAE:PA 0.77 % 0.00 %

N/A

N/A
QRH:CA 0.00 % 1.20 %

N/A

N/A
JPED 0.00 % 0.74 %

N/A

N/A
E908:F Lyxor 1 - TecDAX UCITS ET.. 0.00 % 0.00 %

N/A

N/A
EXS2:F iShares TecDAX UCITS ETF .. 0.00 % 0.00 %

+0.12 (+1.41%)

N/A
C007:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

+0.37 (+1.41%)

USD 0.16B
E907:XETRA Lyxor 1 MDAX (DR) UCITS E.. 0.00 % 0.00 %

+1.74 (+1.41%)

USD 0.13B
ELF1:XETRA Deka MDAX® UCITS ETF 0.00 % 0.00 %

+3.20 (+1.41%)

USD 0.35B
EXS3:XETRA iShares MDAX® UCITS ETF .. 0.00 % 0.00 %

+2.55 (+1.41%)

USD 1.12B
DEAM:XETRA Invesco MDAX® UCITS ETF .. 0.00 % 0.00 %

+0.52 (+1.41%)

USD 0.24B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.32% 46% F 38% F
Dividend Return 2.95% 100% F 62% D
Total Return 5.26% 54% F 39% F
Trailing 12 Months  
Capital Gain -3.53% 31% F 21% F
Dividend Return 2.78% 100% F 41% F
Total Return -0.75% 31% F 21% F
Trailing 5 Years  
Capital Gain 28.09% 25% F 59% D-
Dividend Return 3.69% 60% D- 10% F
Total Return 31.78% 25% F 52% F
Average Annual (5 Year Horizon)  
Capital Gain 3.72% 31% F 53% F
Dividend Return 4.11% 31% F 45% F
Total Return 0.39% 57% F 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 21.28% 85% B 49% F
Risk Adjusted Return 19.31% 31% F 40% F
Market Capitalization 6.46B 33% F 86% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 56.20 25% 4%
Price/Book Ratio 3.02 56% 29%
Price / Cash Flow Ratio 22.38 33% 15%
Price/Free Cash Flow Ratio 30.49 11% 9%
Management Effectiveness  
Return on Equity 2.07% 33% 36%
Return on Invested Capital 6.70% 33% 55%
Return on Assets 1.75% 33% 45%
Debt to Equity Ratio 24.21% 78% 76%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.